Figure 6

Treatment efficacy on secondary outcomes in study population. (a) Percentage change in CXCL8 and TNF-α transcripts in nasal cells (left) and CXCL8 and TNF-α protein levels in the sputum (right) throughout the study in all treated (blue lines) (weeks 12, 24 of treatment schedule) and untreated (red lines) cohorts (week 12, 24 of observation). (b) Absolute change in ppFEV₁ throughout the study in all treated (blue lines) (weeks 12, 24 of treatment schedule) and untreated (red line) (week 12, 24 of observation) cohorts. (c) Absolute change in ppFEV₁ throughout the study in treated patients who received 4 (dashed line) or 8 (solid line) weeks of combination of cysteamine plus EGCG. Bars are 95% CI. Wk, week. Week 12 and 24 or Week 16 and 28 (italic) indicate the corresponding time points in patients who received the combination treatment for 4 or 8 weeks, respectively. (d and e) Individual value of percentage change from baseline of CXCL8 (left) and TNF-α (right) transcript levels in brushed nasal cells (top) and CXCL8 and TNF-α protein levels in the sputum (bottom) throughout the study. Black lines indicate mean values of treated patients; red lines indicate mean values of untreated patients. In treated cohorts, Week 12 and 24 or Week 16 and 28 (italic) indicate the corresponding time points in the subgroup of patients who received combination treatment for 4 or 8 weeks, respectively